An open clinical trial of thymopentin was conducted on 16 children with severe atopic dermatitis. The patients were treated with injections three times a week of 50 mg thymopentin for six weeks. They were then divided randomly into two groups: group A continued thymopentin for an additional six weeks, and group B were treated with normal saline. Clinical parameters and immunological function were evaluated serially. The total severity score started to decline from baseline significantly three weeks after treatment, and continued throughout the study period in group A but began to flare up in group B two weeks after stopping thymopentin. AlU the eight patients in group A completed the trial but three out of eight in group B dropped out because of flaring up of skin lesion. In vitro production of interleukin-4 tended to decrease and that of interferon gamma tended to increase, but total serum IgE, in vitro IgE synthesis, and abnormaliy low CD8+ CD11b+ suppressor T cells remained unchanged. Histamine releasing factor (HRF), plasma histamine, and respiratory burst activities of polymorphonuclear leucocytes were appreciably decreased after thymopentin treatment.
children.7 Chronic atopic dermatitis may result in significant morbidity, including hospitalisation for control of skin disease and infection, lost school days, psychological trauma from physical disfigurement, and occupational disability. The management of atopic dermatitis has been less than satisfactory. None of the currently available treatments are curative and treatment is empirical. 6 Although the pathogenesis ofatopic dermatitis remains unclear, a number of immunological abnormalities have been described. They include: (i) Raised and sustained serum IgE concentrations, 8 (ii) Impaired T cell function,9 (iii) Decreased natural killer cell activity,'0 (iv) Defective capacity to generate alloreactive cytotoxic T cells,"
(v) Impaired autologous mixed lymphocyte reaction due to defective CD4 responder T cells '2 (vi) Increased cell mediated cytotoxicity against skin fibroblasts,'3 (vii) Most importantly, immunological reconstitution after bone marrow transplantation results in the permanent resolution of eczema in Wiskott-Aldrich syndrome, a primary T cell immunodeficiency with raised serum IgE, providing in vivo evidence that immune defects predispose to the development of eczema. 14 Thymopoietin is a polypeptide hormone of the thymus, originally isolated from bovine thymus extract by its effect on neuromuscular transmission. 5 It is secreted by thymic epithelial cells and has been shown to influence both the differentiation of thymocytes'6 and the function of mature T cells. 17 18 Thymopentin (Timunox, Immunobiology Research Institute, Annandale, NJ) is the active pentapeptide (Arg-Lys-AspVal-Tyr) moiety corresponding to amino acids 32 to 36 of the linear 49 amino acid sequence of thymopoietin. The biological effects of thymopentin mimic those of thymopoietin in all systems in which it has been evaluated. '8 19 
Subjects and methods

SUBJECTS
Sixteen children, nine boys and seven girls, aged 3 to 14 years, were enrolled into this study. significant degree. In vitro production of IFN-r was increased (p<005). No change in IL-6 production was found. Again, those changes were reversed after stopping treatment (group B).
The effect of thymopentin on the distributions of T cell subsets is shown in table 2. When compared with normal controls, the patients The changes of serum immunoglobulin concentrations were followed up serially after thymopentin treatment. IgG and IgM tended to decrease after six weeks of treatment, but not to a significant degree. No change was found for IgA, IgE, and in vitro IgE production throughout the course of trial (table 3 ). Figure 4 demonstrates that both plasma histamine and HRF activity were much higher in patients than in normal controls (p<O0OOl for the former and p<O00l for the latter). After thymopentin treatment, both plasma histamine and HRF were decreased significantly. The decrease persisted in group A but reversed to pretreatment value in group at the 12th week Weeks after starting treatment Figure 5 Respiratory burst activities ofpolymorphonuclear leucocytes stimulated by PMA. For chemiluminescence, ***p< 001, ***p<000l;for superoxide production, * * *p<0-001, * * *p<0.001;for hydrogen peroxide production, * * *p<0-001, * * -p<0001. Data are expressed as mean (SEM). Weeks after starting treatment Figure 6 Respiratory burst activities ofpolymorphonuclear leucocytes stimulated by serum opsonised zymosan. For superoxide production, * * *p<O OOI, * * *p<0001;for hydrogen peroxide production, * * *p<0001 , *p<0 OI. Data are expressed as mean (SEM).
heightened activity decreased to normal after treatment. A similar tendency was found when polymorphonuclear leucocytes were stimulated with opsonised zymosan ( fig 6) ; their enhanced activation returned after discontinuation of thymopentin (group B).
Discussion
All patients responded to thymopentin treatment. The itching, scratching, and erythema decreased appreciably three weeks after treatment (fig 1) , and the improved skin texture due to subsidence of papulovesicles and lichenification usually occurred later (fig 2) . The improvement continued in those patients (group A) who received thymopentin treatment throughout the 12 week period, however, the eczema flared up in all patients of group B four weeks after discontinuation of thymopentin (fig 1) . The use of topical steroids and antihistamines could be reduced and no serious side effects were observed except transient pain at the injection site. The beneficial clinical response was largely similar to that reported by Kang et a122 and Leung et al. 23 The immunological mechanism(s) responsible for the clinical efficacy of thymopentin has not been well studied. Cooper et al reported that It is important to note that HRF and plasma histamine concentrations were decreased after thymopentin treatment (fig 4) . Furthermore, the augmented activation of polymorphonuclear leucocytes was also suppressed, as evidenced by the lessened respiratory burst activities (fig 5  and 6 If you can achieve high immunisation rates you automatically create an interesting problem in ethics. The natural disease is now rare and most complications arise from the vaccine. So why not cheat? Why not encourage everybody else to have their babies immunised but leave yours alone? It would have to be secret, of course, because, if everybody else tumbled to the same ruse your baby would finish up at high risk of the disease again. Why should we be concerned about the welfare of others? You may have a theology based explanation but non-theological ethicists seem to debate the matter endlessly without coming to any satisfactory conclusion.' 
